Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity Drugs

Kailera Therapeutics’ IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue. The post Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity Drugs appeared first on MedCity…

Read More

Debunked Episode 30: ACCESS Tries to Succeed Where VBC Fails, AI, and UnitedHealth Gets the Last Week Tonight Treatment

Debunked Podcast co-hosts Arundhati Parmar and Samir Batra discussed the merits of the CMS ACCESS Model (Advancing Chronic Care with Effective, Scalable Solutions) and how it can offer a path to advance value-based care goals. The post Debunked Episode 30: ACCESS Tries to Succeed Where VBC Fails, AI, and UnitedHealth Gets the Last Week Tonight…

Read More

Culina Health Snags $7.9M to Expand Access to Nutrition Care

Culina Health’s Series A round was led by Healthworx, the investment arm of insurer CareFirst. It also included participation from Rethink Impact, Collab Capital, Collide Capital, Vamos Ventures, Tensility Venture Partners, Cake Ventures and GW Ventures. The post Culina Health Snags $7.9M to Expand Access to Nutrition Care appeared first on MedCity News.

Read More